Cargando…

Co-targeting of IGF1R/mTOR pathway by miR-497 and miR-99a impairs hepatocellular carcinoma development

Persistent activation of IGF1R/mTOR signaling pathway plays crucial role in the development of hepatocellular carcinoma (HCC). Therefore, our goal was to elucidate microRNAs (miRNAs) targeting IGF1R/mTOR and the therapeutic potential of single or dual miRNA on HCC development. In this study, we foun...

Descripción completa

Detalles Bibliográficos
Autores principales: Cheng, Henghui, Xue, Jin, Yang, Shouhua, Chen, Yaobin, Wang, Yu, Zhu, Yuanli, Wang, Xiaoyan, Kuang, Dong, Ruan, Qiurong, Duan, Yaqi, Wang, Guoping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5564620/
https://www.ncbi.nlm.nih.gov/pubmed/28624790
http://dx.doi.org/10.18632/oncotarget.18207
_version_ 1783258270698307584
author Cheng, Henghui
Xue, Jin
Yang, Shouhua
Chen, Yaobin
Wang, Yu
Zhu, Yuanli
Wang, Xiaoyan
Kuang, Dong
Ruan, Qiurong
Duan, Yaqi
Wang, Guoping
author_facet Cheng, Henghui
Xue, Jin
Yang, Shouhua
Chen, Yaobin
Wang, Yu
Zhu, Yuanli
Wang, Xiaoyan
Kuang, Dong
Ruan, Qiurong
Duan, Yaqi
Wang, Guoping
author_sort Cheng, Henghui
collection PubMed
description Persistent activation of IGF1R/mTOR signaling pathway plays crucial role in the development of hepatocellular carcinoma (HCC). Therefore, our goal was to elucidate microRNAs (miRNAs) targeting IGF1R/mTOR and the therapeutic potential of single or dual miRNA on HCC development. In this study, we found that miR-497 and miR-99a that target the 3′-UTR of both IGF1R and mTOR were down-regulated in HCC human tissues and cell lines. Functional assay revealed that ectopic expression of miR-497 or miR-99a in HCC cells resulted in a significant inhibition on tumor growth and invasiveness in vitro and tumor development in vivo via repressing the expression of IGF1R and mTOR. Such inhibitory effect on tumor growth is reversed by application of IGF1 ((IGF1R ligand) or MHY1485 (mTOR agonist) in vitro. Furthermore, we found that simultaneous over-expression of both miR-497 and miR-99a exhibited much stronger inhibitory effects on tumor growth than their individual effect, which is still correlated with significantly stronger repression of IGF1R and mTOR. Overall, our results suggest that miR-497 and miR-99a both function as tumor-suppressive miRNAs by suppressing IGF1R/mTOR signaling pathway. The synergistic actions of these two miRNAs partly correlated with IGF1R and mTOR levels, which may represent new strategies for the molecular treatment of HCC.
format Online
Article
Text
id pubmed-5564620
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Impact Journals LLC
record_format MEDLINE/PubMed
spelling pubmed-55646202017-08-23 Co-targeting of IGF1R/mTOR pathway by miR-497 and miR-99a impairs hepatocellular carcinoma development Cheng, Henghui Xue, Jin Yang, Shouhua Chen, Yaobin Wang, Yu Zhu, Yuanli Wang, Xiaoyan Kuang, Dong Ruan, Qiurong Duan, Yaqi Wang, Guoping Oncotarget Research Paper Persistent activation of IGF1R/mTOR signaling pathway plays crucial role in the development of hepatocellular carcinoma (HCC). Therefore, our goal was to elucidate microRNAs (miRNAs) targeting IGF1R/mTOR and the therapeutic potential of single or dual miRNA on HCC development. In this study, we found that miR-497 and miR-99a that target the 3′-UTR of both IGF1R and mTOR were down-regulated in HCC human tissues and cell lines. Functional assay revealed that ectopic expression of miR-497 or miR-99a in HCC cells resulted in a significant inhibition on tumor growth and invasiveness in vitro and tumor development in vivo via repressing the expression of IGF1R and mTOR. Such inhibitory effect on tumor growth is reversed by application of IGF1 ((IGF1R ligand) or MHY1485 (mTOR agonist) in vitro. Furthermore, we found that simultaneous over-expression of both miR-497 and miR-99a exhibited much stronger inhibitory effects on tumor growth than their individual effect, which is still correlated with significantly stronger repression of IGF1R and mTOR. Overall, our results suggest that miR-497 and miR-99a both function as tumor-suppressive miRNAs by suppressing IGF1R/mTOR signaling pathway. The synergistic actions of these two miRNAs partly correlated with IGF1R and mTOR levels, which may represent new strategies for the molecular treatment of HCC. Impact Journals LLC 2017-05-24 /pmc/articles/PMC5564620/ /pubmed/28624790 http://dx.doi.org/10.18632/oncotarget.18207 Text en Copyright: © 2017 Cheng et al. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (http://creativecommons.org/licenses/by/3.0/) (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Paper
Cheng, Henghui
Xue, Jin
Yang, Shouhua
Chen, Yaobin
Wang, Yu
Zhu, Yuanli
Wang, Xiaoyan
Kuang, Dong
Ruan, Qiurong
Duan, Yaqi
Wang, Guoping
Co-targeting of IGF1R/mTOR pathway by miR-497 and miR-99a impairs hepatocellular carcinoma development
title Co-targeting of IGF1R/mTOR pathway by miR-497 and miR-99a impairs hepatocellular carcinoma development
title_full Co-targeting of IGF1R/mTOR pathway by miR-497 and miR-99a impairs hepatocellular carcinoma development
title_fullStr Co-targeting of IGF1R/mTOR pathway by miR-497 and miR-99a impairs hepatocellular carcinoma development
title_full_unstemmed Co-targeting of IGF1R/mTOR pathway by miR-497 and miR-99a impairs hepatocellular carcinoma development
title_short Co-targeting of IGF1R/mTOR pathway by miR-497 and miR-99a impairs hepatocellular carcinoma development
title_sort co-targeting of igf1r/mtor pathway by mir-497 and mir-99a impairs hepatocellular carcinoma development
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5564620/
https://www.ncbi.nlm.nih.gov/pubmed/28624790
http://dx.doi.org/10.18632/oncotarget.18207
work_keys_str_mv AT chenghenghui cotargetingofigf1rmtorpathwaybymir497andmir99aimpairshepatocellularcarcinomadevelopment
AT xuejin cotargetingofigf1rmtorpathwaybymir497andmir99aimpairshepatocellularcarcinomadevelopment
AT yangshouhua cotargetingofigf1rmtorpathwaybymir497andmir99aimpairshepatocellularcarcinomadevelopment
AT chenyaobin cotargetingofigf1rmtorpathwaybymir497andmir99aimpairshepatocellularcarcinomadevelopment
AT wangyu cotargetingofigf1rmtorpathwaybymir497andmir99aimpairshepatocellularcarcinomadevelopment
AT zhuyuanli cotargetingofigf1rmtorpathwaybymir497andmir99aimpairshepatocellularcarcinomadevelopment
AT wangxiaoyan cotargetingofigf1rmtorpathwaybymir497andmir99aimpairshepatocellularcarcinomadevelopment
AT kuangdong cotargetingofigf1rmtorpathwaybymir497andmir99aimpairshepatocellularcarcinomadevelopment
AT ruanqiurong cotargetingofigf1rmtorpathwaybymir497andmir99aimpairshepatocellularcarcinomadevelopment
AT duanyaqi cotargetingofigf1rmtorpathwaybymir497andmir99aimpairshepatocellularcarcinomadevelopment
AT wangguoping cotargetingofigf1rmtorpathwaybymir497andmir99aimpairshepatocellularcarcinomadevelopment